Dr. El-Khoueiry on Choosing Between Lenvatinib and Sorafenib in HCC

Описание к видео Dr. El-Khoueiry on Choosing Between Lenvatinib and Sorafenib in HCC

Anthony El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, distinguishes between lenvatinib and sorafenib for the frontline treatment of advanced hepatocellular carcinoma.

Комментарии

Информация по комментариям в разработке